Autoimmune hemolytic anemia screening: Difference between revisions
Jump to navigation
Jump to search
Iqra Qamar (talk | contribs) |
Sargun Walia (talk | contribs) |
||
| Line 8: | Line 8: | ||
==Screening== | ==Screening== | ||
* Screening for autoimmune hemolytic anemia is not currently done routinely. | * Screening for autoimmune hemolytic anemia is not currently done routinely. | ||
* The incidence of autoimmune hemolytic anemia is low enough such that screening measures are not indicated. | * The [[incidence]] of autoimmune hemolytic anemia is low enough such that screening measures are not indicated. | ||
* However, screening is done for other conditions associated with hemolytic anemia, such as [[Sickle-cell disease|sickle cell disease]].<ref name="pmid27785945">{{cite journal| author=Alapan Y, Fraiwan A, Kucukal E, Hasan MN, Ung R, Kim M et al.| title=Emerging point-of-care technologies for sickle cell disease screening and monitoring. | journal=Expert Rev Med Devices | year= 2016 | volume= 13 | issue= 12 | pages= 1073-1093 | pmid=27785945 | doi=10.1080/17434440.2016.1254038 | pmc=5166583 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27785945 }} </ref> | * However, screening is done for other conditions associated with [[hemolytic anemia]], such as [[Sickle-cell disease|sickle cell disease]].<ref name="pmid27785945">{{cite journal| author=Alapan Y, Fraiwan A, Kucukal E, Hasan MN, Ung R, Kim M et al.| title=Emerging point-of-care technologies for sickle cell disease screening and monitoring. | journal=Expert Rev Med Devices | year= 2016 | volume= 13 | issue= 12 | pages= 1073-1093 | pmid=27785945 | doi=10.1080/17434440.2016.1254038 | pmc=5166583 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27785945 }} </ref> | ||
* One important manifestation of sickle cell disease is hyperhemolytic crisis, in which there is massive [[hemolysis]]. | * One important manifestation of [[Sickle-cell disease|sickle cell disease]] is hyperhemolytic crisis, in which there is massive [[hemolysis]]. | ||
* The United States and the United Kingdom have formal screening processes in place for sickle cell disease for newborns. | * The United States and the United Kingdom have formal screening processes in place for [[Sickle-cell disease|sickle cell disease]] for newborns. | ||
* Screening for sickle cell disease can prevent early childhood morbidity and mortality. | * Screening for [[Sickle-cell disease|sickle cell disease]] can prevent early childhood [[morbidity]] and [[mortality]]. | ||
* Less developed countries, such as countries in Africa, do not have formal screening measures for [[sickle cell disease]] in place.<ref name="pmid27785945">{{cite journal| author=Alapan Y, Fraiwan A, Kucukal E, Hasan MN, Ung R, Kim M et al.| title=Emerging point-of-care technologies for sickle cell disease screening and monitoring. | journal=Expert Rev Med Devices | year= 2016 | volume= 13 | issue= 12 | pages= 1073-1093 | pmid=27785945 | doi=10.1080/17434440.2016.1254038 | pmc=5166583 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27785945 }} </ref> | * Less developed countries, such as countries in Africa, do not have formal screening measures for [[sickle cell disease]] in place.<ref name="pmid27785945">{{cite journal| author=Alapan Y, Fraiwan A, Kucukal E, Hasan MN, Ung R, Kim M et al.| title=Emerging point-of-care technologies for sickle cell disease screening and monitoring. | journal=Expert Rev Med Devices | year= 2016 | volume= 13 | issue= 12 | pages= 1073-1093 | pmid=27785945 | doi=10.1080/17434440.2016.1254038 | pmc=5166583 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27785945 }} </ref> | ||
Latest revision as of 14:18, 10 August 2018
|
Autoimmune hemolytic anemia Microchapters |
|
Differentiating Autoimmune hemolytic anemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune hemolytic anemia screening On the Web |
|
American Roentgen Ray Society Images of Autoimmune hemolytic anemia screening |
|
Directions to Hospitals Treating Autoimmune hemolytic anemia |
|
Risk calculators and risk factors for Autoimmune hemolytic anemia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shyam Patel [2], Irfan Dotani [3]
Overview
Screening for autoimmune hemolytic anemia is not currently done routinely.
Screening
- Screening for autoimmune hemolytic anemia is not currently done routinely.
- The incidence of autoimmune hemolytic anemia is low enough such that screening measures are not indicated.
- However, screening is done for other conditions associated with hemolytic anemia, such as sickle cell disease.[1]
- One important manifestation of sickle cell disease is hyperhemolytic crisis, in which there is massive hemolysis.
- The United States and the United Kingdom have formal screening processes in place for sickle cell disease for newborns.
- Screening for sickle cell disease can prevent early childhood morbidity and mortality.
- Less developed countries, such as countries in Africa, do not have formal screening measures for sickle cell disease in place.[1]
References
- ↑ 1.0 1.1 Alapan Y, Fraiwan A, Kucukal E, Hasan MN, Ung R, Kim M; et al. (2016). "Emerging point-of-care technologies for sickle cell disease screening and monitoring". Expert Rev Med Devices. 13 (12): 1073–1093. doi:10.1080/17434440.2016.1254038. PMC 5166583. PMID 27785945.